Drug Interactions between Jaypirca and venetoclax

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with P-glycoprotein inhibitors (P-gp) may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. Administration of venetoclax with a single dose of rifampin, a P-gp inhibitor when given acutely, increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of venetoclax by 106% and 78%, respectively. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.

MANAGEMENT: In patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), concomitant use of P-gp inhibitors with venetoclax at its steady daily dosage (after the ramp-up dosage titration phase) should generally be avoided. Some authorities advise that the concomitant use of P-gp inhibitors with venetoclax should also be avoided at initiation and during the dose titration phase in patients with CLL/SLL. However, if coadministration is required, the manufacturer recommends the venetoclax dosage be reduced by at least 50% of the original dose for patients with CLL/SLL as well as patients with acute myeloid leukemia (AML) All patients, regardless of indication, should be monitored closely for signs and symptoms of venetoclax-related adverse effects/toxicities and the dosage modified accordingly. In addition, the dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.